The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
Open accessThe DOI matches its Crossref record; 158 of the 165 references it cites were found in a registry or an index.
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with a poor prognosis, associated with asbestos exposure. Nowadays, treatment is based on chemotherapy with a median overall survival of less than two years. This review highlights the main characteristics of the immune microenvironment in MPM with special emphasis on recent biological advances. The MPM microenvironment is highly infiltrated by tumour-associated macrophages, mainly M2-macrophages. In line with infiltration by M2-macrophages, which contribute to immune suppression, other effectors of innate immune response are deficient in MPM, such as dendritic cells or natural killer cells. On the other hand, tumour infiltrating lymphocytes (TILs) are also found in MPM, but CD4+ and CD8+ TILs might have decreased cytotoxic effects through T-regulators and high expression of immune checkpoints. Taken together, the immune microenvironment is particularly heterogeneous and can be considered as mainly immunotolerant or immunosuppressive. Therefore, identifying molecular vulnerabilities is particularly relevant to the improvement of patient outcomes and the assessment of promising treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These “frustrated macrophages” release oxidative mediators and pro-inflammatory cytokines that sustain an inflamed environment and trigger signaling pathways in transformed mesothelial cells that help them to survive, despite the asbestos-related damage [31]”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634 · cited 2×
“Through the secretion of IL-12, myeloid DCs induce polarization of naïve CD4+ T-cells into Th1 cells and, thus, induce a specific immune response [41].”
BackgroundCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 3×
“These cells are described in the concept of immunoediting, which reflects anti-tumour response in three phases: elimination, equilibrium and escape [89].”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 3×
“Immune checkpoint pathways are involved in self-tolerance and prevent tissue from damage causes by excessive immune response [99].”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 8×
“Moreover, in vitro experiments on MT-2 human polyclonal T-cells with chronic exposure to asbestos fibres revealed that regulatory T-cells have enhanced functions through high expression of interleukin-10 and Transforming Growth Factor-betta (TGF-β) [19].”
BackgroundInfluentialTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · cited 1×
“Nowadays, the first-line chemotherapy for MPM is the combination of cisplatin with pemetrexed, since this combination showed efficacy versus cisplatin alone [27,28].”
BackgroundThe biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975 · cited 2×
“CD56bright NKs are CD16dim or CD16- [48].”
BackgroundInnate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824 · cited 1×
“NKs express various activating (NKG2D, 2B4, NKp46) or suppressive (NKG2A, NKG2B, killer cell immunoglobulin-like receptors, CD94) receptors on their surface, which contribute to the activation or suppression of cytotoxicity [49,50].”
BackgroundInnate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389 · cited 2×
“ILCs are divided into five groups according to cytokine production: NK cells, ILC1 (IFN-γ production as NK cells), ILC2 (IL-5, IL-13), ILC3 (IL-22, IL-17) and lymphoid tissue-inducer cells [55,56].”
Background
Cited by
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
“Phagocytic macrophages, unable to eliminate fibers, release oxidative molecules and pro-inflammatory cytokines that promote a pro-inflammatory environment and activate signaling pathways in tumor cells that help them to survive despite the asbestos-related damage [80].”
BackgroundPonce, S., Cedrés, S., Ricordel, C., Isambert, N., Viteri, S., Herrera, M., Martínez‐Martí, A., Navarro, A., Léderlin, M., Serres, X., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007552 · Cited by 46
Theranostic signature of tumor-derived exosomes in cancer
Kumar, S., Dhar, R., Kumar, L., Shivji, G. G., Jayaraj, R., & Devi, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-02176-6 · Cited by 37
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Perrino, M., Vincenzo, F. D., Cordua, N., Borea, F., Aliprandi, M., Santoro, A., & Zucali, P. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121557 · Cited by 34
Metadata
- Authors
- Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E.
- Affiliations
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Pathology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
- Department of Pulmonology and Thoracic Oncology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-06-26
- Volume
- 13
- Issue
- 13
- Pages
- 3205
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8269097
- OpenAlex
- W3175991011
- Cited by
- 34
- References
- 165
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 3 · 2023: 9 · 2022: 7 · 2021: 2
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- malignant pleural mesothelioma, tumor immune microenvironment, tumour-associated macrophages, M2 macrophages, immunosuppression, dendritic cells, natural killer cells, tumor-infiltrating lymphocytes, regulatory T cells, immune checkpoint, asbestos exposure, immunotherapy targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review. https://app.cochat.ai/papers/10.3390/cancers13133205
- The paper
- Désage, A.-L., Karpathiou, G., Peoc’h, M., & Froudarakis, M. E. (2021). The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review. Cancers. https://doi.org/10.3390/cancers13133205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.